Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab for Newly Diagnosed Glioblastoma: a Prospective, Open-label, Single-arm, Multicenter Phase II Study

NCT03899857 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT03899857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03899857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab for Newly Diagnosed Glioblastoma: a Prospective, Open-label, Single-arm, Multicenter Phase II Study
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 21, 2020
Completion date
December 31, 2026
Enrollment
56 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed glioblastoma